Le Lézard
Classified in: Science and technology, Business
Subject: ERN

IFS announces best Q1 results in company history with 26% increase in ARR YoY and 20% increase in Cloud revenue YoY


New CEO visits 100 customers in first 100 days

LONDON, May 2, 2024 /PRNewswire/ -- IFS, the global cloud enterprise software company, today announced its financial results for the first quarter ending March 31, 2024. The results reflect the best start to the year in company history ? an early victory for new CEO Mark Moffat, who was appointed on January 9th, 2024.

Summary of Q1 results:      

A steadfast customer focus positions IFS as the demonstrable leader in all of the segments it serves. A position reinforced thanks to recent industry analyst reports recognizing IFS as the #1 vendor in terms of market share for Enterprise Asset Management (EAM) and Service Management.

IFS CEO Mark Moffat commented: "In my first 100 days as CEO, I have met with over 100 customers around the world, and they consistently tell me that our customer-centric approach is a key differentiator, especially in a world where we see our competitors peddling their own agenda over that of their customers'.

"Our Q1 results are the continuation of our relentless focus on what makes us successful: listening to and delivering value to our customers. It's also what enables us to outperform the market quarter after quarter. Our customer focus is not only ingrained in our culture, but it also extends across our partner ecosystem and the work they deliver alongside us."

Moffat added: "Industrial AI is a huge opportunity for our customers, and we are uniquely positioned to help them harness its potential. We have been developing industry-specific AI solutions that integrate seamlessly with our existing products and leverage the data we have to deliver game-changing outcomes." Moffat concluded: "IFS has an edge because we have been having these conversations with our customers for years, and that has informed how we shape our technology and services. The results of the first quarter show that we are on the right track, and that our vision resonates."

Key factors supporting IFS's expansion:        

IFS Chief Financial Officer, Matthias Heiden, added, "Market conditions in 2024 are still volatile which puts our performance trajectory into context. 26 percent ARR increase year-on-year combined with strong subscriptions renewals is setting us up for continued steady growth in 2024." Heiden continued: "This means we are able to prioritize investment in people and in technology bringing even more innovation into our bi-annual releases." Heiden concluded: "We have worked hard to get to this point, and we are seeing financial benefits deep into our business with all the metrics continuing to accelerate in the right direction."

Investments in key markets such as the US, Europe, and Japan are slated to continue through 2024, bolstering regional performance by driving increased demand for IFS.ai. In Q1 the company also launched a significant brand campaign across the US, including out-of-home advertising at the largest airports in North America, becoming the Big Ten Conference's Official Technology Partner, and a Patron of MIT's Center for Information Systems Research.

IFS is also pleased to today publish the 2023 IFS Sustainability Report, which details the company's strategy, approach and achievements delivering on its own sustainability targets as well as supporting customers to achieve their ESG goals. The report, alongside an ESG Fact Sheet, is available here: https://www.ifs.com/assets/all-products/ifs-sustainability-report-2023

Financial Highlights for Q1 FY2024:      

For more information about IFS's historical financial performance, please visit: https://www.ifs.com/about/financial-information.

Contact information.

EUROPE / MEA / APJ: Adam Gillbe
IFS, Director of Corporate & Executive Communications
Email: https://www.ifs.com/about/financial-information

Phone: +44 7775 114 856
NORTH AMERICA / LATAM: Mairi Morgan
FS, Director of Corporate & Executive Communications
Email: https://www.ifs.com/about/financial-information.
Phone: +44 7018 607 299

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/ifs/r/ifs-announces-best-q1-results-in-company-history-with-26--increase-in-arr-yoy-and-20--increase-in-cl,c3968167

The following files are available for download:

https://mb.cision.com/Main/855/3968167/2760913.pdf

Release

https://news.cision.com/ifs/i/ifs-q1-2024-930x423,c3293966

IFS-Q1-2024-930x423

 

SOURCE IFS


These press releases may also interest you

at 06:02
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major...

at 06:00
Amplify10, the trailblazer in SaaS AI-Powered Sales Execution solutions, proudly announces its official launch today, aimed at reshaping the landscape of sales performance for enterprises worldwide. The early-stage company, formerly known as...

at 06:00
Quhuo Limited ("Quhuo" or the "Company") , a leading gig economy platform focusing on local life services in China, today announced that Ms. Chenxi Zhao has resigned from her position as a member of the board of directors (the "Board"), effective on...

at 05:50
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...

at 05:45
A report from China.org.cn:  China Duty Free Group (CDFG), the world's leading travel retail operator, outlined its strategy for continued growth at the recently concluded TFWA Asia Pacific Exhibition & Conference held in Singapore from May 12 to...

at 05:35
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...



News published on and distributed by: